Type of information: Nomination
Company: Oryzon Genomics (Spain)
Type agreement: nomination
- • On May 16, 2017, Oryzon Genomics announced that Roger Bullock has been appointed Chief Medical Officer (CMO). This appointment strengthens the company's epigenetic leadership with a veteran of neurological and psychiatric disorders who brings extensive clinical and medical experience in the field of Alzheimer’s disease, Huntington’s disease and other neurodegenerative disorders.
Dr. Bullock graduated in Physiological Sciences at Keble College in Oxford University and got his MB.BS at London University. He specialized in Old Age medicine and in
neurodegenerative and neuropsychiatric disorders. He has extensive experience as clinical researcher, having participated in more than 70 clinical trials in Alzheimer’s disease and other CNS conditions. Over his 30-year research career, he has authored and co-authored more than 100 peer-reviewed publications and book chapters in this domain and presented at numerous conferences. Recently he has
been working as a consultant for companies active in the CNS space, including Lilly and Merck. With the addition of Dr. Bullock, Dr. César Molinero will transition from his current dual position as Chief Medical and Clinical Operations Officer to concentrate on the role of Chief Clinical Officer. The medical department of Oryzon will further enhance its capabilities with the incorporation of additional clinical
- In his new capacity, Dr. Bullock will be responsible for executing the clinical development plan of the
epigenetic drugs developed by the company, notably ORY-2001, an oral dual LSD1-MAOB inhibitor
currently finishing Phase I in healthy volunteers. The company presented positive top line data from this clinical trial in the ADPD meeting in Vienna in March and is planning to start later this year several Phase II clinical trials with ORY-2001 in different neurodegenerative disorders, including Alzheimer’s disease and multiple sclerosis.